Security
Cellectar Biosciences, Inc. Common Stock · CLRB
CLRBNASDAQCommon stockCurrentCIK 1279704Updated Oct 6, 2026
Name history
NOVELOS THERAPEUTICS, INC. · through Feb 11, 2014COMMON HORIZONS INC · through Jun 2, 2005
CLRB price & chart
Loading TradingView…
NASDAQ:CLRB on TradingView ↗About the company
We are a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid ether drug conjugate™ (PDC™) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. We believe that our PDC platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments, and we plan to develop PDCs both independently and through research and development collaborations.
In the news
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026 ↗
Seeking Alpha
Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy Transcript ↗
Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy - Slideshow ↗
Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript ↗
Recent filings
SCHEDULE 13G - filed by Caligan Partners LP regarding Cellectar Biosciences, Inc.
SCHEDULE 13G - filed by STEMPOINT CAPITAL LP regarding Cellectar Biosciences, Inc.
SCHEDULE 13G - filed by BALYASNY ASSET MANAGEMENT L.P. regarding Cellectar Biosciences, Inc.
SCHEDULE 13G - filed by Bleichroeder LP regarding Cellectar Biosciences, Inc.
Results of Operations and Financial Condition
Items 2.02, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 14,627,590Source | 37,293,266Source | 36,639,086Source | 13,695,183Source | 29,384,657Source | 11,119,761Source | 16,042,190Source | 42,908,439Source | 14,978,321Source | 25,474,047Source | 14,838,456Source | 21,589,790Source |
| Property, Plant and Equipment, NetUSD | 595,271Source | 910,131Source | 304,173Source | 647,549Source | 978,701Source | 339,697Source | 700,826Source | 1,023,447Source | 549,405Source | 757,121Source | 376,084Source | 418,641Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 12,554,289Source | 34,263,371Source | 33,993,982Source | 11,041,027Source | 25,868,907Source | 8,347,090Source | 13,905,173Source | 40,031,181Source | 13,196,033Source | 23,288,607Source | 12,682,691Source | 19,866,358Source |
| Assets, CurrentUSD | 13,621,698Source | 35,899,189Source | 34,877,641Source | 12,617,606Source | 27,905,360Source | 9,267,128Source | 14,892,668Source | 41,368,365Source | 14,038,465Source | 24,250,272Source | 13,846,436Source | 20,529,601Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,067,409Source | 1,635,818Source | 883,659Source | 1,576,579Source | 2,036,453Source | 920,038Source | 987,495Source | 1,337,184Source | 842,432Source | 961,665Source | 1,163,745Source | 663,243Source |
| Operating Lease, Right-of-Use AssetUSD | 380,841Source | 454,166Source | 1,433,706Source | 400,248Source | 470,816Source | 1,483,156Source | 418,916Source | 486,847Source | 360,671Source | 436,874Source | 546,505Source | 560,334Source |
| Other Assets, NoncurrentUSD | 29,780Source | 29,780Source | 23,566Source | 29,780Source | 29,780Source | 29,780Source | 29,780Source | 29,780Source | 29,780Source | 29,780Source | 69,431Source | 6,214Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 5,248,261Source | 20,746,303Source | 6,767,253Source | 6,228,148Source | 15,621,661Source | 6,402,651Source | 6,406,778Source | 29,025,321Source | 5,059,134Source | 9,797,343Source | 12,085,450Source | 6,082,271Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 520,778Source | — | — | 520,778Source | — | 520,778Source | — | — | — | — | — | 1,382,023Source |
| Common Stock, Value, IssuedUSD | 32Source | 406Source | 83Source | 18Source | 358Source | 42Source | 461Source | 332Source | 42Source | 461Source | 97Source | 94Source |
| Additional Paid in CapitalUSD | 271,314,776Source | 246,536,080Source | 311,589,849Source | 264,958,619Source | 234,859,383Source | 277,601,713Source | 261,678,642Source | 224,836,048Source | 277,149,844Source | 261,115,905Source | 168,551,763Source | 193,624,445Source |
| Retained Earnings (Accumulated Deficit)USD | -263,838,280Source | -244,987,090Source | -281,718,099Source | -259,394,403Source | -230,322,371Source | -274,787,446Source | -253,946,492Source | -229,403,000Source | -269,133,500Source | -247,342,463Source | -167,180,877Source | -179,499,043Source |
| Stockholders' Equity Attributable to ParentUSD | 7,997,306Source | 15,164,940Source | 29,871,833Source | 6,085,012Source | 12,380,973Source | 3,335,087Source | 8,253,389Source | 12,501,095Source | 8,537,164Source | 14,294,681Source | 1,370,983Source | 15,507,519Source |
| Liabilities and EquityUSD | 14,627,590Source | 37,293,266Source | 36,639,086Source | 13,695,183Source | 29,384,657Source | 11,119,761Source | 16,042,190Source | 42,908,439Source | 14,978,321Source | 25,474,047Source | 14,838,456Source | 21,589,790Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 4,912,366Source | 20,314,374Source | 5,237,711Source | 5,866,661Source | 15,168,153Source | 4,873,826Source | 6,020,575Source | 28,550,972Source | 4,749,737Source | 9,387,757Source | 11,537,106Source | 5,529,290Source |
| Operating Lease, Liability, CurrentUSD | 96,034Source | 80,821Source | 2,030Source | 92,022Source | 77,348Source | — | 88,146Source | 73,994Source | 100,189Source | 84,417Source | 51,106Source | 50,847Source |
| Accounts Payable, CurrentUSD | — | — | — | — | — | — | — | — | 1,441,000Source | 4,105,000Source | — | 2,558,000Source |
| Operating Lease, Liability, NoncurrentUSD | 335,895Source | 431,929Source | 1,529,542Source | 361,487Source | 453,508Source | 1,528,825Source | 386,203Source | 474,349Source | 309,397Source | 409,586Source | 548,344Source | 552,981Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | — | 56,295Source | 213,597Source | 291,653Source | — | 148,435Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 451,869Source | 562,737Source | 2,263,704Source | 4,272,780Source | — | 1,452,964Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -6,854,000Source | -19,563,445Source | — | -10,433,496Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -4,845,565Source | -9,383,434Source | -23,118,217Source | -47,583,001Source | — | -25,222,301Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -3,378Source | — | -5,880Source | -104,195Source | — | -225,971Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 3,378Source | — | 5,880Source | 104,195Source | — | 225,971Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | — | 13,031,523Source | 61,410,815Source | — | 9,610,655Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -4,848,943Source | -9,383,434Source | -10,092,574Source | 13,723,619Source | — | -15,837,617Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 12,554,289Source | 34,263,371Source | 33,993,982Source | 11,041,027Source | 8,347,090Source | 13,905,173Source | 13,196,033Source | 23,288,607Source | 12,682,691Source | 19,866,358Source |
| Additional Financial Items | ||||||||||||
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | — | -145,726Source | — | -3,386Source |
| General and Administrative ExpenseUSD | — | — | 2,327,391Source | 7,834,181Source | 2,638,629Source | 3,647,728Source | 2,786,713Source | 2,973,896Source | 11,481,083Source | 25,641,452Source | — | 9,594,170Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 66,000Source | — | -60,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -4,443,877Source | -14,664,719Source | -6,930,653Source | -5,447,911Source | -5,653,946Source | -6,604,029Source | -21,791,037Source | -44,581,446Source | — | -28,601,254Source |
| Nonoperating Income (Expense)USD | — | — | 406,819Source | -1,337,042Source | 265,359Source | 589,618Source | 139,996Source | -203,038Source | 1,188,807Source | 7,262,252Source | — | 152,519Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | — | 9,610,655Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -4,850,696Source | -13,327,677Source | -7,196,012Source | -6,037,529Source | -5,793,942Source | -6,400,991Source | -22,979,844Source | -51,777,698Source | -38,960,643Source | -28,813,773Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -21,791,037Source | -44,515,446Source | -42,830,610Source | -28,661,254Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 66,000Source | -60,000Source | -60,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -4,443,877Source | -14,664,719Source | -6,930,653Source | -5,447,911Source | -5,653,946Source | -6,604,029Source | -21,791,037Source | -44,581,446Source | -42,770,610Source | -28,601,254Source |
| Earnings Per Share, BasicUSD per share | — | — | -1.41Source | -11.18Source | -0.57Source | -3.39Source | -1.33Source | -4.3Source | -8.35Source | -1.22Source | -3.5Source | -4.05Source |
| Earnings Per Share, DilutedUSD per share | — | — | -1.41Source | -12.13Source | -0.57Source | -3.39Source | -1.33Source | -4.3Source | -8.35Source | -1.4Source | -3.5Source | -4.05Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 3,162,040Source | 1,311,197Source | 12,231,851Source | 1,608,799Source | 4,240,129Source | 1,535,995Source | 2,608,317Source | 36,622,474Source | 12,221,571Source | 7,055,665Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 3,162,040Source | 1,326,474Source | 12,231,851Source | 1,608,799Source | 4,240,129Source | 1,535,995Source | 2,608,317Source | 37,143,769Source | 12,221,571Source | 7,055,665Source |
| Additional Financial Items | ||||||||||||
| Costs and ExpensesUSD | — | — | 4,850,696Source | 13,327,677Source | 7,196,012Source | 6,037,529Source | 5,793,942Source | 6,400,991Source | 22,979,844Source | 51,777,698Source | 38,960,643Source | 28,813,773Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 66,000Source | -60,000Source | -60,000Source |
| General and Administrative ExpenseUSD | — | — | 2,327,391Source | 7,834,181Source | 2,638,629Source | 3,647,728Source | 2,786,713Source | 2,973,896Source | 11,481,083Source | 25,641,452Source | 11,694,367Source | 9,594,170Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 112,543Source | 317,887Source | 133,359Source | 88,020Source | 62,996Source | 136,962Source | 435,100Source | 1,210,853Source | 387,147Source | 152,519Source |
| Nonoperating Income (Expense)USD | — | — | 406,819Source | -1,337,042Source | 265,359Source | 589,618Source | 139,996Source | -203,038Source | 1,188,807Source | 7,262,252Source | -3,869,967Source | 152,519Source |
| Research and Development ExpenseUSD | — | — | 2,523,305Source | 5,493,496Source | 4,557,383Source | 2,389,801Source | 3,007,229Source | 3,427,095Source | 11,498,761Source | 26,136,246Source | 27,266,276Source | 19,219,603Source |
Offerings
Registration 333-296036
Registration 333-290971
Registration 333-288333
- Gross proceeds
- 5999997.0
- Net proceeds
- 5519997.0
- Deal price
- 5.0
- Shares
- 1199999
- Offering price
- $5.00
- Ticker
- CLRB
Registration 333-284580
Filing attachments
tm2621614d1_ex99-1.htm · SCHEDULE 13G · 2026-08-14
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of th…
Read attachment ↗ex99-1.htm · SCHEDULE 13G · 2026-08-13
Exhibit 99.1 AGREEMENT OF THE REPORTING PERSONS The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and ac…
Read attachment ↗tm2623056d1_ex99-1.htm · 8-K · 2026-08-13
EX-99.1 2 tm2623056d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program Presented Data from CLOVER WaM Trial of Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) at the American Society of Clinical …
Read attachment ↗tm2614602d1_ex99-1.htm · 8-K · 2026-05-14
EX-99.1 2 tm2614602d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.S. FDA Filing for Accelerated Approval Efficacy Results from r/r WM Patients…
Read attachment ↗tm2613728d1_ex4-1.htm · 8-K · 2026-05-08
EX-4.1 2 tm2613728d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT…
Read attachment ↗tm2613728d1_ex4-2.htm · 8-K · 2026-05-08
EX-4.2 3 tm2613728d1_ex4-2.htm EXHIBIT 4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT…
Read attachment ↗